Bisphosphonates or RANK‐ligand‐inhibitors for men with prostate cancer and bone metastases: a network meta‐analysis

Review of 25 trials suggests that zoledronic acid likely increases both the proportion of participants with pain response, and the proportion of participants experiencing adverse events However, more trials with head‐to‐head comparisons are needed.

Source:

Cochrane Database of Systematic Reviews